Literature DB >> 20798232

Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.

Shuko Nojiri1, Kenichi Gemba, Keisuke Aoe, Katsuya Kato, Takuhiro Yamaguchi, Tsugumichi Sato, Kiyoshi Kubota, Takumi Kishimoto.   

Abstract

OBJECTIVE: The objective in our study was to examine baseline and other characteristics associated with survival in patients with malignant pleural mesothelioma in Japan.
METHODS: Three hundred and fourteen patients with an adjudicated diagnosis of mesothelioma were examined. Survival was evaluated by the Kaplan-Meier method with the log-rank test. The Cox model was used to estimate the hazard ratio for the possible prognostic factors.
RESULTS: Of 314 patients, 223 (71%) died and only 40 (13%) were still alive at the end of the observation period starting from the day of diagnosis, while 51 (16%) were transferred to other hospitals or had the last health service contact before the end of the study period yielding the median survival of 308 days. In the multivariate analysis, age older than 70 years (hazard ratio = 2.17; 95% confidence interval, 1.36-3.46), non-epithelioid type (hazard ratio = 1.58; 95% confidence interval, 1.15-2.18), poor performance status (hazard ratio = 3.22; 95% confidence interval, 1.19-8.74), high white blood cell count (hazard ratio = 1.49; 95% confidence interval, 0.99-2.26) and high C-reactive protein level (hazard ratio = 1.80; 95% confidence interval, 1.06-3.06) were negatively associated with survival, after adjustment for other factors.
CONCLUSIONS: Some baseline conditions including old age, poor performance status, non-epithelioid type, high white blood cell count and high C-reactive protein level were determinants of poor survival of patients with malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798232     DOI: 10.1093/jjco/hyq159

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  22 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 2.  Volumetric assessment in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Izidor Kern; Andrej Cör
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-23       Impact factor: 4.553

5.  Metastatic biphasic pleural mesothelioma presenting with cauda equina syndrome.

Authors:  Pritesh Pranay; Viktor Serafimov; Julia Hall; Amit Goel; Majid Mushtaq
Journal:  Radiol Case Rep       Date:  2018-05-18

6.  Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Jože Pižem; Izidor Kern; Viljem Kovač; Maja Cemažar; Andrej Cör
Journal:  Virchows Arch       Date:  2013-01-29       Impact factor: 4.064

7.  Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.

Authors:  Zhou-Hong Yao; Guang-Yan Tian; Shao-Xiang Yang; Yun-Yan Wan; Yan-Meng Kang; Qing-Hua Liu; Fei Yao; Dian-Jie Lin
Journal:  Tumour Biol       Date:  2014-04-15

8.  Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.

Authors:  Hidekazu Suzuki; Kazuhiro Asami; Tomonori Hirashima; Norio Okamoto; Tadahiro Yamadori; Motohiro Tamiya; Naoko Morishita; Takayuki Shiroyama; Sawa Takeoka; Akio Osa; Yuichiro Azuma; Kyoichi Okishio; Tomoya Kawaguchi; Shinji Atagi; Ichiro Kawase
Journal:  Lung       Date:  2013-10-20       Impact factor: 2.584

9.  Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.

Authors:  Takehiro Otoshi; Yuki Kataoka; Sawako Kaku; Reika Iki; Masataka Hirabayashi
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

10.  CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Authors:  Vishwa Jeet Amatya; Yukio Takeshima; Keisuke Aoe; Nobukazu Fujimoto; Toshihiro Okamoto; Taketo Yamada; Takumi Kishimoto; Chikao Morimoto; Kouki Inai
Journal:  Oncol Rep       Date:  2012-10-31       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.